Max Rosett - 29 Jul 2025 Form 4 Insider Report for Immunome Inc. (IMNM)

Reporting owner
Role
Chief Financial Officer
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Issuer context
Issuer symbol
IMNM
Transaction snapshot
Transactions as of
29 Jul 2025
Net transaction value
$0
SEC evidence
Form type
4
Filing time
31 Jul 2025, 18:59:16 UTC
Previous filing
20 Sep 2024
Next filing
03 Apr 2026
SEC filing
View on sec.gov

Key filing fact

Max Rosett filed Form 4 for Immunome Inc. (IMNM) on 31 Jul 2025.

Key facts

  • This page summarizes Max Rosett's Form 4 filing for Immunome Inc. (IMNM).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 31 Jul 2025, 18:59.

Change

  • Previous filing in this sequence was filed on 20 Sep 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001994071 Primary reporting owner

Rosett Max

Relationship
Chief Financial Officer
Address
C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Signature date
31 Jul 2025

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

IMNM transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
$0
Shares
+207,000
Change %
Price
$0.000000
Shares after
207,000
Date
29 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
207,000
Exercise price
$10.60
Footnotes
F1
* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .